Fast Market Research announces the availability of the new GBI Research report, "Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth", on their comprehensive research portal
Boston, MA -- (SBWIRE) -- 02/04/2016 -- Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5-7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.
However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth.
Get More Details on this Report and a Full Table of Contents at Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth
Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.
-What factors are driving the market growth?
-How can the factors limiting growth be overcome?
There is a very large pharmaceutical pipeline for immunology, consisting of 1,838 products in active development. However, the commercial performance of the products in the late-stage pipeline is expected to be moderate.
-What gaps in the market are being addressed by the most promising of these late-stage pipeline products?
-How does the composition of the pipeline compare with that of the existing market?
Several key commercially successful products, including Humira (adalimumab) and Remicade, are due to lose patent protection in the forecast period.
-How will this affect their revenues in this period?
-How are their manufacturers, AbbVie and Johnson & Johnson, responding to this?
The key players in the market, all of which are among the top 20 pharmaceutical companies, are expected to maintain their market lead throughout the forecast period.
-What is driving this continued market dominance?
-Who will the new market players be?
Reasons to Get this Report
This report will allow you to -
-Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
-Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
-Analyze the immunology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
-Understand the growth in patient epidemiology and market revenues for the immunology market globally and across the key players and product types
-Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological disorders
-Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals
Companies Mentioned in this Report: AbbVie, Johnson & Johnson, Amgen, Genentech/Roche, Astellas, UCB, Eli Lilly, Sanofi, AstraZeneca, Novartis
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
-PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
-Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations
-Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth
-Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth
-Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth